Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System - Advances in Therapy
Source : https://link.springer.com/article/10.1007/s12325-022-02346-4
Introduction Through 2018, three calcitonin gene-related peptide pathway-targeted monoclonal antibodies (CGRP mAbs) had received US Food and Drug Administration (FDA) approval for migraine prevention: erenumab, fremanezumab, and galcanezumab.
Conclusions: "Conclusion: These results aid in supporting the safety profile of CGRP mAbs in the real-world setting and may provide clinicians and patients with additional insight when considering migraine preventive treatments."
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrGood to know.
Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta-analysis of the efficacy and safety of randomized controlled trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36373822/
Background: Migraine is a worldwide epidemic neurological disorder that has a significant influence on the quality of life. Migraine attacks are considered to be related to a calcitonin gene-related peptide...
Conclusions: In our study, we found that erenumab, especially at the dose of 140 mg, is an effective and well-tolerated preventive treatment for migraine.
"
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrGood study, to help determine doses.
Predictors of treatment-response to acute prescription medications in migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study
Source : https://www.sciencedirect.com/science/article/abs/pii/S0303846722003924?via=ihub
To identify predictors of acute treatment optimization with prescription drugs among people with episodic migraine. A total of 2896 individuals from the American Migraine Prevalence and Prevention study were included...
/>
Conclusions: Almost half of study respondents were not optimized on their usual prescription acute migraine treatment(s). Predictive models identified several features associated with treatment optimization.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrInteresting study!
Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study - The Journal of Headache and Pain
Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01511-y
Objective HER-MES was the first head-to-head, phase 4 trial to assess the tolerability and effectiveness of erenumab against standard of care treatment (topiramate). This post hoc analysis compared the efficacy...
Conclusions: This post hoc analysis demonstrated significantly superior efficacy of erenumab versus topiramate in achieving a ≥50% reduction in MMD with an early onset of efficacy."
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrVery important study.
-
Migraine Connect3yrKey Points • Source: The Journal of Headache and Pain • Conclusion: “This post hoc analysis demonstrated significantly superior efficacy of erenumab versus topiramate in achieving a ≥50% reduction in MMD [monthly migraine days] Show More
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36404301/
doi: 10.1186/s10194-022-01514-9. 1 Chinese PLA General Hospital, Beijing, China. [email protected]. 2 Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea. 3 Hebei General Hospital, Shijiazhuang, China. 4 The...
Conclusions: "DRAGON study demonstrated the efficacy and safety of erenumab 70 mg in patients with CM from Asia. No new safety signals were observed during the DBTP compared with the previous trials."
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThis is an important study.